In a controlled, laboratory-based pilot study, patients with AD underwent 10 or 20 sessions of tACS at the gamma frequency, and brain magnetic resonance imaging (MRI), positron emission tomography (PET) for amyloid, tau or microglial activation, electroencephalography (EEG), and neuropsychological evaluations were completed before and after the intervention. The gene discussed is MAPT; the disease is Alzheimer disease.